📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Arvinas

1.1 - Company Overview

Arvinas Logo

Arvinas

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of PROTAC protein degrader therapies that harness the body's natural protein disposal system to degrade disease-causing proteins for life-threatening diseases, from discovery to commercialization. Pipeline includes vepdegestrant (ER+ breast cancer), ARV-766 (licensed to Novartis; prostate cancer), ARV-393 (BCL6), ARV-102 (LRRK2), and alpha-synuclein degraders.

Products and services

  • Vepdegestrant: An oral PROTAC protein degrader targeting the estrogen receptor to treat ER+ breast cancer disease
  • ARV-766: A PROTAC androgen receptor protein degrader for prostate cancer, licensed to Novartis for development and commercialization
  • ARV-393: An investigational PROTAC designed to degrade B-cell lymphoma 6 protein, implicated in B cell lymphomas

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Arvinas

ProfoundBio Logo

ProfoundBio

HQ: United States Website
  • Description: Provider of antibody-based cancer therapeutics, including antibody-drug conjugates. Clinical-stage pipeline includes Rina-S, a folate receptor alpha-targeting ADC for ovarian and other solid tumors (Phase 2); PRO1160, a CD70-targeting ADC for solid tumors and hematological malignancies (Phase 1/2); PRO1107, a PTK7-targeted ADC with a hydrophilic MMAE-based linker-drug (Phase 1/2); and PRO1286, a bispecific EGFR/cMET ADC (trials anticipated in 2024).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ProfoundBio company profile →
RadiaDyne Logo

RadiaDyne

HQ: United States Website
  • Description: Provider of medical diagnostics and devices; privately held.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full RadiaDyne company profile →
Cirrus Bio Logo

Cirrus Bio

HQ: United States Website
  • Description: Provider of solutions for common health issues that impact well-being.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cirrus Bio company profile →
YM BioSciences Logo

YM BioSciences

HQ: Canada Website
  • Description: Provider of life sciences product development services focused on identifying and advancing a diverse portfolio of cancer-related products at various stages of development, leveraging regulatory and clinical trial expertise and a diversified business model to reduce risk while advancing clinical products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full YM BioSciences company profile →
Orionis Biosciences Logo

Orionis Biosciences

HQ: United States Website
  • Description: Provider of biotechnology platforms for healthcare innovation, including the A-Kine platform for engineering cytokines with targeted cell selectivity and controlled activity for cancer immunotherapy, and the Allo-Glue platform for discovering and designing small molecule molecular glues to modulate or degrade disease targets.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Orionis Biosciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Arvinas

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Arvinas

2.2 - Growth funds investing in similar companies to Arvinas

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Arvinas

4.2 - Public trading comparable groups for Arvinas

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Arvinas

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Arvinas

What does Arvinas do?

Arvinas is a provider of PROTAC protein degrader therapies that harness the body's natural protein disposal system to degrade disease-causing proteins for life-threatening diseases, from discovery to commercialization. Pipeline includes vepdegestrant (ER+ breast cancer), ARV-766 (licensed to Novartis; prostate cancer), ARV-393 (BCL6), ARV-102 (LRRK2), and alpha-synuclein degraders.

Who are Arvinas's competitors?

Arvinas's competitors and similar companies include ProfoundBio, RadiaDyne, Cirrus Bio, YM BioSciences, and Orionis Biosciences.

Where is Arvinas headquartered?

Arvinas is headquartered in United States.

How many employees does Arvinas have?

Arvinas has 1,000 employees 🔒.

When was Arvinas founded?

Arvinas was founded in 2010 🔒.

What sector and industry vertical is Arvinas in?

Arvinas is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Arvinas

Who are the top strategic acquirers in Arvinas's sector and industry

Top strategic M&A buyers and acquirers in Arvinas's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Arvinas?

Top strategic M&A buyers groups and sectors for Arvinas include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Arvinas's sector and industry vertical

Which are the top PE firms investing in Arvinas's sector and industry vertical?

Top PE firms investing in Arvinas's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Arvinas's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Arvinas's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Arvinas's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Arvinas include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Arvinas's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Arvinas?

The key public trading comparables and valuation benchmarks for Arvinas include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Arvinas for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Arvinas with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Arvinas's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Arvinas with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Arvinas's' sector and industry vertical?

Access recent funding rounds and capital raises in Arvinas's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Arvinas